Purple Biotech (PPBT) vs XORTX Therapeutics (XRTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
XORTX Therapeutics is the larger company by market cap ($1.9 million vs $1.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPBT | XRTX |
|---|---|---|
| Share price | $1.53 | $0.839 |
| Market cap | $1.86M | $1.88M |
| 1-day change | -4.09% | -5.73% |
| Forward P/E | — | 1.05 |
| EPS (TTM) | $-47.64 | $-2.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-26.39M | — |
| 52-week high | $8.90 | $3.60 |
| 52-week low | $0.91 | $0.81 |
| Distance from 52-week high | -82.87% | -76.69% |
| Analyst consensus | none | — |
| Avg. price target upside | +1014.75% | — |
| Average volume | 1.26M | 776.48K |
| Shares outstanding | 1.22M | 2.25M |
| Employees | 10 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About XORTX Therapeutics
XRTX stock →XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Health Care · Biotechnology: Pharmaceutical Preparations
PPBT vs XRTX FAQ
Which is bigger, Purple Biotech or XORTX Therapeutics?
XORTX Therapeutics (XRTX) is larger, with a market capitalization of $1.88M compared with $1.86M for Purple Biotech (PPBT).
Are Purple Biotech and XORTX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.